bpc-157 fda compounding category Peptide Crackdown: What Pharmacists Need to Know Survey: Half of Peptide-Users Aren't

Evaluating the Evidence The excitement around peptide therapy reflects a desire for safer, more targeted treatments

Food and Drug Administration (FDA) announced that it will convene a public meeting of the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to consider whether to recommend seven (7) peptide bulk drug substances for inclusion on the list of substances that may be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act

Nowadays when you are ill, you do not rush to a doctor first

Diarrhea affects 16-34% of retatrutide users depending on dose, making it the second most common GI side effect after nausea